Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: Implications for quantitative translational pharmacology

AAPS Journal

Volumn 13, Issue 4, 2011, Pages 576-584

  Maurer, Tristan S ^a   Ghosh, Avijit ^a   Haddish Berhane, Nahor ^a   Sawant Basak, Aarti ^a   Boustany Kari, Carine M ^a   She, Li ^a   Leininger, Michael T ^a   Zhu, Tong ^a   Tugnait, Meera ^a   Yang, Xin ^a   Kimoto, Emi ^a   Mascitti, Vincent ^a   Robinson, Ralph P ^a  

^a PFIZER INC   (United States)

Author keywords

diabetes; glucosuria; pharmacodynamics; pharmacokinetics; SGLT2; translational pharmacology; UGE

Indexed keywords

DAPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ELIMINATION; GLUCOSE ABSORPTION; GLUCOSE URINE LEVEL; GLUCOSURIA; IC 50; MALE; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; RAT; SIMULATION; SPECIES DIFFERENCE;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 83555164888     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9297-2     Document Type: Article

References (41)

1. CDC. National diabetes fact sheet, 2011. 2011.
2. Anonymous 2008 Economic costs of diabetes in the U.S. In 2007 Diabetes Care 31 3 596 615
3. PA Carpino B Goodwin 2010 Diabetes area participation analysis: a review of companies and targets described in the 2008-2010 patent literature Expert Opin Ther Pat 20 12 1627 1651 21083519 10.1517/13543776.2010.533171 1:CAS:528:DC%2BC3cXhsVekt7fP
4. NA Hosea WT Collard S Cole TS Maurer RX Fang H Jones, et al. 2009 Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches J Clin Pharmacol 49 5 513 533 19299532 10.1177/0091270009333209 1:CAS:528:DC%2BD1MXlsFWmu74%3D
5. M Jamei GL Dickinson A Rostami-Hodjegan 2009 A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates Drug Metab Pharmacokinet 24 1 53 75 19252336 10.2133/dmpk.24.53 1:CAS:528:DC%2BD1MXks1Whu7o%3D
6. SS De Buck VK Sinha LA Fenu MJ Nijsen CE Mackie RAHJ Gilissen 2007 Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs Drug Metab Dispos 35 10 1766 1780 17620347 10.1124/dmd.107.015644 (Pubitemid 47481568)
7. HM Jones N Parrott K Jorga T Lave 2006 A novel strategy for physiologically based predictions of human pharmacokinetics Clin Pharmacokinet 45 5 511 542 16640456 10.2165/00003088-200645050-00006 1:CAS:528: DC%2BD28Xlt1Kgsbo%3D
8. RS Obach 1999 Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Drug Metab Dispos 27 11 1350 1359 10534321 1:CAS:528:DyaK1MXntFSht7c%3D
9. RS Obach JG Baxter TE Liston BM Silber BC Jones F Macintyre, et al. 1997 The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J Pharmacol Exp Ther 283 1 46 58 9336307 1:CAS:528: DyaK2sXmslCltr0%3D (Pubitemid 27438945)
10. C Emoto N Murayama A Rostami-Hodjegan H Yamazaki 2010 Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution Curr Drug Metab 11 8 678 685 20973757 10.2174/138920010794233503 1:CAS:528:DC%2BC3cXhs1artrfE
11. N Blanchard NJ Hewitt P Silber H Jones P Coassolo T Lave 2006 Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations J Pharm Pharmacol 58 5 633 641 16640832 10.1211/jpp.58.5.0008 1:CAS:528:DC%2BD28XpsFKgtrg%3D
12. DF McGinnity J Collington RP Austin RJ Riley 2007 Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs Curr Drug Metab 8 5 463 479 17584017 10.2174/138920007780866799 1:CAS:528:DC%2BD2sXnsl2jtL4%3D (Pubitemid 47603410)
13. KW Ward BR Smith 2004 A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time Drug Metab Dispos 32 6 612 619 15155552 10.1124/dmd.32.6.612 1:CAS:528:DC%2BD2cXktlOgtrs%3D (Pubitemid 38668153)
14. KW Ward BR Smith 2004 A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance Drug Metab Dispos 32 6 603 611 15155551 10.1124/dmd.32.6.603 1:CAS:528:DC%2BD2cXktlOgtro%3D (Pubitemid 38668152)
15. H Tang M Mayersohn 2006 A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry J Pharm Sci 95 8 1783 1799 16795013 10.1002/jps.20481 1:CAS:528: DC%2BD28XnvF2itLk%3D (Pubitemid 44229585)
16. I Mahmood 2004 Interspecies pharmacokinetic scaling: principles, applications, and limitations Pharmacokinet Drug Dev 1 423 444 1:CAS:528:DC%2BD2MXisVaqtbs%3D
17. JB Houston 1994 Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance Biochem Pharmacol 47 9 1469 1479 8185657 10.1016/0006-2952(94)90520-7 1:CAS:528:DyaK2cXkt1Kju7c%3D (Pubitemid 24167255)
18. I Kola J Landis 2004 Opinion: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 8 711 716 15286737 10.1038/nrd1470 1:CAS:528:DC%2BD2cXmtVOhtLs%3D
19. WN Washburn 2009 Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents Expert Opin Ther Pat 19 11 1485 1499 19852718 10.1517/13543770903337828 1:CAS:528:DC%2BD1MXhtlWmu7jK
20. LP van den Heuvel K Assink M Willemsen L Monnens 2002 Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) Hum Genet 111 6 544 547 12436245 10.1007/s00439-002-0820-5 (Pubitemid 36075086)
21. R Santer M Kinner CL Lassen R Schneppenheim P Eggert M Bald, et al. 2003 Molecular analysis of the SGLT2 gene in patients with renal glucosuria J Am Soc Nephrol 14 11 2873 2882 14569097 10.1097/01.ASN.0000092790.89332.D2 1:CAS:528:DC%2BD3sXotFWnt74%3D (Pubitemid 37305650)
22. J Calado K Soto C Clemente P Correia J Rueff 2004 Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria Hum Genet 114 3 314 316 14614622 10.1007/s00439-003-1054-x (Pubitemid 38208311)
23. JF List V Woo E Morales W Tang FT Fiedorek 2009 Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 4 650 657 19114612 10.2337/dc08-1863 1:CAS:528:DC%2BD1MXltFSksrc%3D
24. CJ Bailey JL Gross A Pieters A Bastien JF List 2010 Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 375 9733 2223 2233 20609968 10.1016/S0140-6736(10)60407-2 1:CAS:528:DC%2BC3cXotVagtro%3D
25. W Meng BA Ellsworth AA Nirschl PJ McCann M Patel RN Girotra G Wu PM Sher EP Morrison SA Biller R Zahler PP Deshpande A Pullockaran DL Hagan N Morgan JR Taylor MT Obermeier WG Humphreys A Khanna L Discenza JG Robertson A Wang S Han JR Wetterau EB Janovitz OP Flint JM Whaley WN Washburn 2008 Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J Med Chem 51 1145 1149 18260618 10.1021/jm701272q 1:CAS:528:DC%2BD1cXhvFWgtrY%3D (Pubitemid 351480378)
26. B Komoroski N Vachharajani D Boulton D Kornhauser M Geraldes L Li, et al. 2009 Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin Pharmacol Ther 85 5 520 526 19129748 10.1038/clpt.2008.251 1:CAS:528:DC%2BD1MXkslKqu7o%3D
27. Mascitti V, Maurer TS, Robinson RP, Bian J, Boustany-Kari CM, Brandt T, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors. J Med Chem. 2011; in press, published online at http://pubs.acs.org/doi/pdfplus/ 10.1021/jm200049r.
28. RM Chamberlain DG Shirley 2007 Time course of the renal functional response to partial nephrectomy: measurements in conscious rats Exp Physiol 92 1 251 262 17085677 10.1113/expphysiol.2006.034751 1:CAS:528:DC%2BD2sXjsVeitr4%3D (Pubitemid 46096269)
29. K-C Shih L-Y Liu C-F Kwok C-M Hwu C-C Juan Y-P Hsu, et al. 2007 Effect of reversing dark-light cycles on normal diurnal variation and related metabolic disturbance in rats Chin J Physiol 50 2 69 76 17608144 1:CAS:528: DC%2BD2sXkvFynu70%3D
30. T Jolin A Montes 1973 Daily rhythm of plasma glucose and insulin levels in rats Horm Res 4 3 153 156 4748471 10.1159/000178303 1:CAS:528: DyaE3sXksVSmsLk%3D
31. T Matsuo K Izumori 2006 Effects of dietary D-psicose on diurnal variation in plasma glucose and insulin concentrations of rats Biosci Biotechnol Biochem 70 9 2081 2085 16960391 10.1271/bbb.60036 1:CAS:528:DC%2BD28XhtFSjtbbK (Pubitemid 44451883)
32. CL Rohlfing H-M Wiedmeyer RR Little JD England A Tennill DE Goldstein 2002 Defining the relationship between plasma glucose and HbA1c: Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial Diabetes Care 25 2 275 278 11815495 10.2337/diacare.25.2.275 1:CAS:528:DC%2BD38Xhtlyksrk%3D (Pubitemid 41079621)
33. DM Nathan J Kuenen R Borg H Zheng D Schoenfeld RJ Heine 2008 Translating the A1C assay into estimated average glucose values Diabetes Care 31 8 1473 1478 18540046 10.2337/dc08-0545 1:CAS:528:DC%2BD1cXhtVWlur3L
34. RS DeWoskin CM Thompson 2008 Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants Regul Toxicol Pharmacol 51 1 66 86 18433959 10.1016/j.yrtph.2008.02. 005 1:CAS:528:DC%2BD1cXmtVSntro%3D
35. Beal SL, Boeckmann AJ, Sheiner LB. NONMEM Users Guides, Version 5 edition. San Francisco: University of California at San Francisco; 1999.
36. S Han DL Hagan JR Taylor L Xin W Meng SA Biller, et al. 2008 Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats Diabetes 57 6 1723 1729 18356408 10.2337/db07-1472 1:CAS:528:DC%2BD1cXnsF2isL4%3D
37. EM Wright 2001 Renal Na(+)-glucose cotransporters Am J Physiol Renal Physiol 280 1 F10 F18 11133510 1:CAS:528:DC%2BD3MXjtVyku7g%3D
38. AJ Voogel MG Koopman AA Hart GA van Montfrans L Arisz 2001 Circadian rhythms in systemic hemodynamics and renal function in healthy subjects and patients with nephrotic syndrome Kidney Int 59 5 1873 1880 11318959 10.1046/j.1523-1755.2001.0590051873.x 1:STN:280:DC%2BD3Mvitlaisg%3D%3D (Pubitemid 32336803)
39. RS Mazze E Strock D Wesley S Borgman B Morgan R Bergenstal, et al. 2008 Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis Diabetes Technol Ther 10 3 149 159 18473688 10.1089/dia.2007.0293 1:CAS:528:DC%2BD1cXlvFynsrw%3D (Pubitemid 351677595)
40. L Zhang Y Feng J List S Kasichayanula M Pfister 2010 Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight Diabetes, Obes Metab 12 6 510 516 10.1111/j.1463-1326.2010.01216.x 1:CAS:528:DC%2BC3cXnsFOltrs%3D
41. EK Hussey RL Dobbins RR Stoltz NL Stockman RL O'Connor-Semmes A Kapur, et al. 2010 Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study J Clin Pharmacol 50 6 636 646 20200268 10.1177/0091270009352185 1:CAS:528:DC%2BC3cXns1CgsL8%3D